Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Pediatricians in Private Practice (US)(?)

Council Members in this Study Group: 336

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

Michael Blaiss, MD, Partner, Allergy & Asthma CareMichael Blaiss, MD
Partner
Allergy & Asthma Care

Michael S. Blaiss, MD, is a Clinical Professor of Pediatrics and Medicine at University of Tennessee Health Sciences Center and in private practice at Allergy & Asthma Care in Memphis. Dr. Blaiss’s clinical focus is on allergies and has expertise in outcomes research in allergic disorders, especially...

Mark Vandewalker, MD
Allergy Specialist and Partner
Allergy & Asthma Consultants Of The Ozarks Ltd

Mark Vandewalker, MD, is an Allergy Specialist at Allergy and Asthma Consultants and he is the Medical Director at Clinical Research of the Ozarks in Missouri. Dr. Vandewalker is board-certified in Pediatric Allergy and has been practicing for almost 25 years. His areas of expertise include allergic...

GLG NewsSMAnalyses by this Study Group's Leading Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
cold medications overdose- med fault or Dr. fault? | 10-06-2008
Author: GLG Expert Contributor

There is a alot of information in the media  about the dangers of givng OTC cough medication to young children . Many children have ended up in the emergency room after "over-ingesting" "cold remedy products that include OTC antihistamines, decongestants and  cough suppressants. Also when...

Published Evidence Bias: Approved Drugs Are Just the Tip of the Iceberg | 09-29-2008
Analysis of: Many Trial Reports on FDA-Approved Drugs Go Unpublished | www.washingtonpost.com
Author: GLG Expert Contributor

This study looked at drugs that were eventually approved by the FDA, and found that only 43% of early phase (non-"pivotal") trials were published in the medical literature.  But imagine what this means for drugs that ultimately fail: if drugs that are destined for success are withholding 57% of...

At What Cost Prevention? | 08-06-2008
Author: GLG Expert Contributor

There is already a bounty of data to support anti-retroviral (and other) HIV medications in post-exposure prophylaxis, be it in infants born to HIV-positive mothers; intra-partum prophylaxis to HIV-positive women in active labor; and to healthcare workers (and others) exposed to HIV from accidental...

Will Xolair Become Obsolete in the Treatment of Allergies? | 06-10-2008
Author: Mark Vandewalker, MD, Allergy Specialist and Partner, Allergy & Asthma Consultants Of The Ozarks Ltd

This recent report characterizes a newly discovered anti-IgE monoclonal antibody (mAb12) which appears dramatically more potent than omalizumab (Xolair) in its ability to reduce systemic IgE levels. If further studies confirm this enhanced reduction of IgE and IgE-bearing cells, mAb12 has significant...

No One is Paying $30K For One More Month | 06-02-2008
Author: GLG Expert Contributor

Or whatever the total cost of Erbitux is that is required to get you four more weeks of life.  This is basically what it comes down to.  Most cost-benefit analyses will justify up to $60K spent per year of life in amortized costs, but not above that.  So the total costs of Erbitux...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Office Based Private Practice or Clinic
  • Academic Medical Center/Hospital or Clinic
  • Non-Academic Community Hospital or Clinic

Most Common Job Types:

  • Physician - Attending Physician
  • Owner
  • Partner
  • President
  • Physician - Director
  • Director

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics


Generated at 2008-10-12T01:47:01.177